Financial Data and Key Metrics Changes - The company ended Q1 2025 with a cash position of $204.1 million, which includes approximately $65.5 million in net proceeds from a public offering closed in January 2025 [21] - Total operating expenses for the quarter were $37.8 million, down 82% from the same period in 2024 [22] - Research and development expenses were $22.1 million compared to $36.6 million in Q1 2024, primarily due to decreased spending on AMX-35 for ALS treatment [22] - Selling, general and administrative expenses were $15.7 million compared to $57.8 million in Q1 2024, mainly due to reduced payroll and consulting costs [22] Business Line Data and Key Metrics Changes - The lead asset, Avexatide, is in a pivotal Phase III trial for post-bariatric hypoglycemia (PBH), with the first participant dosed in April 2025 [6][8] - AMX-35 is being evaluated for Wolfram syndrome and progressive supranuclear palsy (PSP), with positive Phase II data reported for Wolfram syndrome [10][12] - AMX-114, targeting ALS, has initiated a Phase I trial with the first participant dosed in April 2025 [13] Market Data and Key Metrics Changes - Approximately 160,000 people in the U.S. are estimated to be living with PBH, a condition with no approved treatment options [7][17] - The American Society for Metabolic and Bariatric Surgery reported around 270,000 new bariatric surgeries in 2023, indicating a stable market for potential PBH patients [18] Company Strategy and Development Direction - The company aims to advance three potential therapies across four clinical trials, focusing on diseases with high unmet needs [6] - The anticipated commercial launch of Avexatide, if approved, is expected in 2027 [8] - The company is preparing for a potential first-to-market launch of Avexatide in PBH, emphasizing the need for patient education and market access strategies [31][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving clinical milestones through the end of 2026, supported by a strong cash position [21][22] - The company is focused on executing its clinical programs and is optimistic about the upcoming data releases from ongoing trials [25][26] Other Important Information - The company has received FDA breakthrough therapy designation for Avexatide, highlighting the high unmet need in PBH [8][82] - The Phase III Lucidity trial is designed to evaluate the reduction in hypoglycemic events, with a robust body of data supporting Avexatide's efficacy [19][20] Q&A Session Summary Question: On Avexatide and patient education needs - Management acknowledged the need for a patient education campaign due to the rarity of PBH and the lack of prior treatments [28][31] Question: Efficacy expectations for PSP - Management indicated the study is powered to detect a 30% effect on the PSP rating scale, with multiple endpoints being considered [34][36] Question: Treatment-seeking behavior in PBH population - Management clarified that while 160,000 are estimated to have PBH, a larger group experiences hypoglycemia post-bariatric surgery, with many seeking treatment [40][42] Question: FDA discussions on trial design - Management stated that the week 48 data will inform the Phase III program, but specific details of FDA discussions were not disclosed [50][54] Question: Subgroup analysis in Avexatide study - Management confirmed that the study focuses on a population with frequent hypoglycemic events, and they do not anticipate step therapy restrictions from payers [58][60] Question: Safety concerns regarding GLP-1 antagonists - Management reassured that Avexatide has shown a good safety profile in clinical trials, with no significant adverse events reported [66][68] Question: Business development activities - Management emphasized a focus on executing current clinical trials rather than pursuing new business development opportunities at this time [70] Question: Inclusion criteria regarding NfL levels in ALS trial - Management explained that while NfL levels are high in ALS patients, they did not set specific high NfL level criteria for trial inclusion to avoid missing important signals [73][75] Question: Comparison of Avexatide to other drugs - Management highlighted Avexatide's strong profile and breakthrough therapy designation, noting that it is well-positioned compared to earlier-stage competitors [80][82]

Financial Data and Key Metrics Changes - The company ended Q1 2025 with 20.6 million members, an increase of approximately 900,000 from the end of 2024 [4] - Revenue for Q1 was $276.7 million, compared to $248 million in the same quarter last year, marking an increase of 11.5% [22] - Adjusted EBITDA was $117 million, an increase of 10.1% year over year, with an adjusted EBITDA margin of 42.3% [25] - Net income was $42.1 million, with adjusted net income at $50 million, reflecting strong financial performance [25] Business Line Data and Key Metrics Changes - System-wide same club sales grew by 6.1% in Q1, with franchisee same club sales increasing by 6.2% and corporate same club sales increasing by 5.1% [21] - Black Card penetration reached approximately 65%, a nearly 300 basis point increase from the previous year [9][22] - Equipment segment revenue increased by 28.7%, driven by higher revenue from replacement equipment sales [23] Market Data and Key Metrics Changes - The company opened 19 new clubs globally, bringing the total club count to 2,741 [4] - Member activity increased, with members visiting clubs an average of 6.7 times per month, the highest utilization in five years [10] - Gen Z continues to lead membership growth, being the fastest-growing demographic since 2021 [10] Company Strategy and Development Direction - The company is focused on four strategic imperatives: redefining brand promise, enhancing member experience, refining product offerings, and accelerating new club growth [6] - The brand is positioned as a leader in the high-value, low-price fitness category, aiming to provide a judgment-free environment [5] - The company plans to continue testing various promotional strategies to drive membership growth [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience and ability to navigate macroeconomic challenges, citing historical performance during economic downturns [5][42] - The company reiterated its growth targets for 2025, expecting to open between 160 and 170 new clubs [28] - Management acknowledged potential tariff impacts but indicated that current levels do not materially affect 2025 targets [15][27] Other Important Information - The company is implementing a click-to-cancel feature to enhance member experience, with over 50% of US clubs already enabled [20] - The company is exploring new equipment offerings and amenities for Black Card members, including red light therapy and spray tanning [88] Q&A Session Summary Question: Regarding Black Card penetration and pricing strategy - Management noted that the increase in Black Card penetration is a result of a successful promotion and the narrowing price gap between Classic and Black Card memberships [34][35] Question: Impact of macroeconomic conditions on business - Management indicated that the business remains resilient, with strong member growth and revenue despite macroeconomic volatility [42][45] Question: Future of franchise ownership and international development - Management highlighted positive franchisee sentiment and strong performance in international markets, particularly in Spain and Australia [106][108] Question: Churn rates and pricing impacts - Churn rates are in line with expectations, and management is monitoring the effects of price increases on member retention [82] Question: Development pipeline and big box availability - Management discussed varying availability of big box spaces across geographies and expressed confidence in the development pipeline despite macro concerns [94][96]

Insmed (INSM) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Thank you for standing by. My name is Amy, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Insmed First Quarter twenty twenty five Financial Results Call. All participants have been placed in a listen only mode. After the speakers' remarks, we will conduct a question and answer session. It is now my pleasure to turn the call over to Brian Dunn. You may begin. Speaker1 Thank you, Amy. ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $412 million, exceeding expectations of approximately $395 million, with a year-over-year growth of over 5% on an ongoing basis and nearly 7% on a constant currency basis [9][35] - Adjusted gross margin increased to 47.3%, up 80 basis points compared to the previous year, driven by a healthier sales mix and lower promotional activity [38] - Adjusted diluted earnings per share improved from $0.05 in Q1 2024 to $0.18 in Q1 2025, above the outlook of $0.10 [38] Business Line Data and Key Metrics Changes - Saucony achieved a revenue growth of 30% year-over-year in Q1, with strong contributions from all regions and channels, particularly in North America [10][36] - Merrell's revenue grew by 13% compared to Q1 last year, with significant contributions from core product franchises [15][36] - Sweaty Betty's revenue declined by 16% in Q1, aligning with expectations, but showed improvement in gross margin due to a shift towards full-price sales [36][22] Market Data and Key Metrics Changes - The company's international business grew mid-teens year-over-year in Q1, indicating strong performance outside the U.S. [30] - U.S. retail sell-through remained strong throughout April, with similar reports from international regions [27] Company Strategy and Development Direction - The company is focused on transforming its culture and building new capabilities to compete effectively in the market [24] - Strategic investments are being made in brand momentum, with a particular emphasis on Saucony and Merrell, while also addressing challenges in the Wolverine brand and Sweaty Betty [19][21] - A diversified and nimble supply chain is being leveraged to mitigate risks associated with tariffs and to optimize product delivery [28][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's prospects despite uncertainties in the marketplace, particularly regarding tariffs and consumer sentiment [26][49] - The decision to withdraw full-year guidance for 2025 was made due to the dynamic nature of the operating environment, but management remains confident in the current order book and DTC trends [39][40] - The company is taking a proactive approach to navigate challenges, focusing on profitability while continuing to invest in brand growth [31][44] Other Important Information - The company has initiated a search for new leadership for the work group as part of its ongoing strategic adjustments [21] - Significant investments are planned for Saucony in 2025, marking the largest investment year since its acquisition [15] Q&A Session Summary Question: Insights on Saucony and Merrell business for the full year - Management indicated that sourcing diversification efforts have reduced reliance on China, and they feel good about the momentum for 2025, with no material changes since April 2 [54][56] Question: Details on price increases to mitigate tariff impacts - Price increases were implemented strategically across brands, with mid-single digit increases for specific products, but these are not expected to fully offset tariff impacts [65][66] Question: Demand planning for the back half of the year - The company is closely monitoring consumer demand and adjusting inventory levels accordingly, with a cautious approach in certain areas while remaining bullish in others [77][79] Question: Promotional activities and margin improvements for Merrell - Management acknowledged ongoing promotional activities but emphasized efforts to reduce them, with a focus on improving gross margins over time [81][82] Question: Breakdown of international business revenue - Management directed to the investor presentation for insights on regional revenue dispersion, indicating a significant portion of revenue is generated outside the U.S. [86]

Financial Data and Key Metrics Changes - Revenue for the first quarter of fiscal 2025 was $412 million, exceeding expectations of approximately $395 million, with a year-over-year growth of over 5% on an ongoing basis and nearly 7% on a constant currency basis [34][7] - Adjusted gross margin increased to 47.3%, up 80 basis points compared to the previous year, driven by a healthier sales mix and lower promotional activity [37] - Adjusted diluted earnings per share improved from $0.05 in Q1 2024 to $0.18 in Q1 2025, surpassing the outlook of $0.10 [37] Business Line Data and Key Metrics Changes - Saucony achieved a revenue growth of 30% year-over-year in Q1, with strong contributions from all regions and channels, particularly in North America [8][35] - Merrell's revenue grew by 13% compared to Q1 last year, with significant contributions from Asia Pacific and EMEA [14][35] - Sweaty Betty's revenue declined by 16% in Q1, aligning with expectations, but showed improvement in gross margin due to a better mix of full-price sales [35][36] Market Data and Key Metrics Changes - The company's international business grew mid-teens year-over-year in Q1, indicating strong performance outside the U.S. [30] - U.S. retail sell-through remained strong throughout April, with similar positive reports from international regions [26][27] Company Strategy and Development Direction - The company is focused on transforming its culture and building new capabilities to compete effectively in the market [24] - A strategic plan is in place to mitigate the impact of tariffs, including diversifying the supply chain and implementing price adjustments [31][32] - The company aims to enhance brand positioning and reduce promotional activities to improve long-term profitability [22][80] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's prospects despite uncertainties in the marketplace, particularly regarding tariffs and consumer sentiment [25][26] - The decision to withdraw full-year guidance for 2025 was made due to the dynamic nature of the operating environment [38] - The company remains committed to investing in brand momentum while managing costs effectively [41][42] Other Important Information - The company has initiated a search for new leadership in the work group as part of its ongoing restructuring efforts [21] - Significant investments are planned for Saucony, marking the largest investment year since its acquisition [14] Q&A Session Summary Question: Insights on the order book and momentum for Saucony and Merrell - Management indicated that sourcing diversification efforts have accelerated, with expectations of sourcing from China dropping below 10% this year [54] - The order book remains strong, and there is confidence in the momentum for 2025 [55] Question: Details on price increases to mitigate tariff impacts - Price increases were implemented strategically across brands, with specific examples provided for Saucony and Merrell [64][65] - These increases are not expected to fully offset tariff impacts, necessitating additional measures [66] Question: Demand planning for the back half of the year - The company has established a new integrated business planning group to better manage inventory and demand signals [75] - There is a cautious approach to inventory management based on brand momentum and market conditions [76] Question: Promotional activities and their impact on Merrell - Management acknowledged the need to reduce promotional activities and improve gross margins, indicating a transition period [80] - The increase in Merrell's revenue was attributed to improved sell-through and a cleaner inventory position [81] Question: Breakdown of international business performance - Insights into regional revenue and unit dispersion were provided, with a focus on the significant contribution from international markets [86]

Financial Data and Key Metrics Changes - In Q1 2025, Carvana reported retail units sold totaling 133,898, an increase of 46% year-over-year, setting a new company record [10] - Revenue reached $4,232,000,000, marking a 38% increase year-over-year and also a new company record [11] - Adjusted EBITDA was $488,000,000, an increase of $253,000,000 year-over-year, with an adjusted EBITDA margin of 11.5%, a 3.8 percentage point increase [14][15] - Non-GAAP retail GPU was $33.08, up $97 year-over-year, while non-GAAP wholesale GPU decreased to $964, down $189 year-over-year [11][12] Business Line Data and Key Metrics Changes - The operations portion of SG&A expense was $16.58 per retail unit sold, a decrease of $192, driven by operational efficiency initiatives [14] - Non-GAAP SG&A expense totaled $468,000,000, an increase of 20%, but the growth in retail units sold led to a $750 reduction in SG&A expense per retail unit sold [13] Market Data and Key Metrics Changes - Carvana currently captures about 1% of the total U.S. used car market, which consists of 40,000,000 used cars and 16,000,000 new cars sold annually [9] Company Strategy and Development Direction - The company aims to grow to $3,000,000 in annual retail sales with 13.5% adjusted EBITDA margins over the next five to ten years, prioritizing growth over margin within reasonable ranges [8][9] - Carvana's mission is to change the way people buy cars by offering a differentiated selection, experience, and value [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic challenges, highlighting that they are currently the most profitable automotive retailer, with significant cash balances and a strong growth trajectory [50][51] - The company anticipates a sequential increase in both retail units sold and adjusted EBITDA in Q2 2025, expecting to set all-time records for both metrics [16] Other Important Information - The company has been focusing on improving customer experience and operational efficiencies, which has led to significant gains in profitability and customer satisfaction [25][30] - Carvana is exploring opportunities in third-party marketplace selling and ancillary revenue streams, although these are not a near-term focus [90][91] Q&A Session Summary Question: Impact of tariffs on financial performance - Management acknowledged that tariffs could potentially drive up car prices, which may benefit used car prices and business models like Carvana's that offer value to consumers [20][21] Question: Trajectory of retail GPU - Management indicated that they are focused on improving various inputs affecting retail GPU and are optimistic about maintaining a strong overall GPU perspective [36][39] Question: Positioning for potential recession - Management highlighted that Carvana is now more profitable and has significant cash reserves, positioning the company better to absorb macroeconomic variations compared to previous years [50][51] Question: Update on lending partnerships - Management confirmed that they have strengthened their securitization program and added new buyers, indicating a robust lending backdrop [56][58] Question: Third-party marketplace selling - Management stated that they are in the early stages of developing offerings related to wholesale and retail marketplace, with potential for faster and lower-cost solutions [90]

Carvana (CVNA) Q1 2025 Earnings Call May 07, 2025 05:30 PM ET Speaker0 afternoon, ladies and gentlemen, and thank you for joining us on Carvana's first quarter twenty twenty five earnings conference call. Please note that this call will be simultaneously webcast on the Investor Relations section of the company's corporate website at investors.carvana.com. The first quarter shareholder letter is also posted on the IR website. Additionally, we posted a set of supplemental financial tables for Q1, which can be ...

Financial Data and Key Metrics Changes - Total net sales for Q1 2025 were $42.6 million, down from $77.4 million in the same quarter last year, primarily due to minimal purchases by distributors in China [26][27] - Adjusted EBITDA for Q1 2025 was a loss of $26.4 million compared to earnings of $5.3 million in the prior year, reflecting a $33 million decrease in gross profit [27][28] - Gross margin for Q1 2025 was 65.8%, down from 78.9% year-over-year, impacted by higher manufacturing costs and increased inventory reserves [29][30] Business Line Data and Key Metrics Changes - Sales in China were $389,000 in Q1 2025, a significant drop from $38.5 million in the same quarter last year, as distributors consumed existing inventory [14][26] - Net sales excluding China were $42.2 million, representing a 9% growth year-over-year, driven by growth in APAC sales outside China [26][28] - The company expects to recognize $27.5 million in sales associated with a prior order in Q3 2025, which will help normalize reported sales in China [14][28] Market Data and Key Metrics Changes - The demand for ICL procedures in China is improving, with expectations for a strong second half of 2025 as inventory levels are managed [10][13] - The company is seeing growth in APAC markets outside China, with Japan, South Korea, and India contributing positively to sales performance [28][29] - The global prevalence of myopia is increasing, which is expected to drive demand for lens-based vision correction solutions [7][41] Company Strategy and Development Direction - The company aims to return to sustainable growth by addressing short-term tactical issues and focusing on strategic growth initiatives [8][10] - A new management structure has been implemented to enhance operational efficiency and drive shareholder value [9][10] - The company is expanding its manufacturing capabilities in Switzerland to mitigate tariff impacts and support future growth [19][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in China and the overall market for ICL procedures, despite global economic uncertainties [33][105] - The company is committed to transparency and aims to build trust with investors by delivering consistent results [60][68] - Management believes that the unique proprietary technology and first-mover advantage will sustain competitive advantages in the market [34][35] Other Important Information - The company has withdrawn its previous guidance due to economic uncertainty and evolving tariff situations, but remains optimistic about future performance [33][60] - The restructuring efforts are expected to continue into Q2, with additional charges anticipated as the company rightsizes its operations [27][28] - The company ended Q1 2025 with $222.8 million in cash and equivalents, with expectations to maintain cash above $140 million through the year [31][32] Q&A Session Summary Question: Can you elaborate on ICL sellout in Q1 2025 and trends for Q2? - Management noted that sellout rates were consistent across January, February, and March, and they are pleased with the pace of sales [46][47] Question: What is the competitive impact of Ibrite on ICL? - Management indicated that competition has been minimal so far, and they welcome it as it raises awareness of alternatives to glasses and contacts [48][50] Question: How does the consignment inventory strategy mitigate tariff impacts? - Management explained that consignment inventory is owned by the company and is positioned with distributors in China to avoid tariffs [17][71] Question: What is the pricing strategy for EVO ICL? - Management stated that there are no major changes in pricing strategy, emphasizing the high value of the EVO ICL to patients and surgeons [76][78] Question: How does the new leadership in China inform the broader strategy? - Management highlighted the importance of having experienced leadership in China to capitalize on opportunities and address challenges effectively [101][102]

Financial Data and Key Metrics Changes - Total net sales for Q1 2025 were $42.6 million, down from $77.4 million in the same quarter last year, primarily due to minimal purchases by distributors in China [24] - Adjusted EBITDA for Q1 2025 was a loss of $26.4 million compared to earnings of $5.3 million in the prior year, reflecting a $33 million decrease in gross profit [26] - Gross margin for Q1 2025 was 65.8%, down from 78.9% in the year-ago quarter, impacted by higher manufacturing costs and increased inventory reserves [28] Business Line Data and Key Metrics Changes - China sales were reported at $389,000 for Q1 2025, a significant drop from $38.5 million in the same quarter last year, as distributors consumed existing inventory [14][24] - Net sales excluding China were $42.2 million, representing a 9% growth year-over-year, driven by growth in APAC sales outside China [27] - The company expects to recognize $27.5 million in sales associated with a prior order in Q3 2025, which was not recognized upon shipment [14] Market Data and Key Metrics Changes - The company noted an improvement in ICL procedures in China, with end market demand strengthening despite the low reported sales [14] - In the Americas, sales growth was 9% in Q1 2025, while EMEA saw a 10% increase, and APAC sales excluding China were up 8% [27] - The prevalence of myopia is increasing globally, which is expected to drive demand for lens-based vision correction solutions [39] Company Strategy and Development Direction - The company aims to return to sustainable growth by addressing short-term tactical issues and focusing on strategic growth initiatives [7][8] - A new management structure has been implemented to enhance efficiency, including the promotion of key executives and the introduction of a Chief Development Officer [9][10] - The company is expanding its manufacturing capabilities in Switzerland to mitigate tariff impacts and increase production capacity [20][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in China and the potential for improved sales in the second half of 2025 [32][102] - The company is committed to transparency and aims to build trust with investors by delivering solid financial results [66] - Management acknowledged the challenges posed by global economic uncertainty but remains confident in the long-term growth potential of the EVO ICL technology [32][39] Other Important Information - The company has withdrawn its previous guidance due to tariff uncertainties and economic conditions but remains optimistic about achieving growth targets [31][60] - The restructuring efforts have resulted in significant charges, but the company believes these actions will lead to improved long-term profitability [25][30] Q&A Session Summary Question: Can you elaborate on ICL sellout in Q1 2025 and trends for Q2? - Management noted that end market sales were consistent across January, February, and March, and they are pleased with the pace of recovery [46] Question: What is the competitive impact of Ibrite on ICL? - Management indicated that competition has been minimal so far, and they welcome it as it raises awareness of surgical options [49][50] Question: How does the company view the current economic trends compared to previous guidance? - Management acknowledged global uncertainty but expressed confidence in hitting revised targets based on improving trends in China [57][60] Question: Can you quantify the consignment inventory in China? - Management stated they have enough inventory to mitigate tariff impacts through early 2026 and are working to align inventory levels with contractual obligations [71][92] Question: What is the pricing strategy for EVO ICL in China and the U.S.? - Management confirmed no major changes in pricing strategy, emphasizing the high value of EVO ICL to patients and surgeons [78]

Financial Data and Key Metrics Changes - In Q4, the company achieved record revenue exceeding $1,000,000,000 for the first time, with full-year revenue surpassing $4,000,000,000 and royalty revenue exceeding $2,000,000,000 [7][8] - Total revenue for Q4 was $1,240,000,000, with royalty revenue growing 18% year-on-year to a record $607,000,000 [13][14] - Licensing revenue increased over 50% year-on-year to a record $634,000,000, driven by demand for ARMv9 technology [14][15] Business Line Data and Key Metrics Changes - Smartphone royalties increased by 30% year-on-year, significantly outpacing the 2% growth in shipments, indicating a rising value per device [10][14] - The company launched its first ARMv9 Edge AI platform, which has been adopted by major players in the industry [10][11] - Custom silicon demand is driving both licensing and royalty growth, with significant contributions from data centers, automotive, smartphones, and IoT [8][10] Market Data and Key Metrics Changes - The company expects up to 50% of new server chips at hyperscalers to be ARM-based this year, reflecting strong momentum in the data center market [8][62] - The automotive sector has shown strong double-digit growth, with ARM gaining market share in advanced driver-assistance systems (ADAS) [60] - IoT and embedded markets have seen some slowness, but growth is expected to continue, albeit at a slower pace compared to other sectors [61] Company Strategy and Development Direction - The company is focusing on customization of silicon to differentiate performance and unlock unique features, particularly in automotive and hyperscaler markets [42][44] - There is a strategic shift towards direct relationships with OEMs, which may impact traditional fabless semiconductor companies [42][45] - The company plans to aggressively invest in R&D to support customer needs and capitalize on the growing demand for AI technologies [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in healthy growth despite macroeconomic uncertainties, citing strong visibility into customer design pipelines and contracted royalty rates [20][21] - The company anticipates limited direct impact from tariffs on royalty and licensing revenues, with potential indirect effects on end demand [16][26] - Future revenue growth is expected to enable increased investment in next-generation technologies [19][20] Other Important Information - The company signed a significant multi-year agreement with the Malaysian government to develop an ARM-based AI ecosystem, indicating potential for future sovereign-level licensing deals [66][68] - The company is seeing strong demand for its compute subsystems, which are now shipping in volume, boosting both mobile and cloud royalty revenue [11][12] Q&A Session Summary Question: Impact of tariffs on revenue - Management clarified that tariffs do not directly impact costs, and any revenue impact would be indirect, primarily affecting demand elasticity [23][25] Question: ARMv9 adoption rate - The adoption rate for ARMv9 has increased to over 30%, driven by custom silicon solutions [32][33] Question: Strategic direction towards OEMs - Management confirmed a trend towards direct relationships with OEMs for customized silicon, which may affect traditional semiconductor companies [42][45] Question: Licensing performance in Q4 - Licensing revenue growth was strong, with a year-on-year increase of 53%, driven by demand for CSS and AI technologies [76][80] Question: Royalty growth by end market - Management indicated strong growth in smartphones and infrastructure, with automotive also showing double-digit growth, while IoT is recovering slowly [60][61] Question: Future of chiplet technology - Management acknowledged the importance of chiplet technology and its integration with ARM's architecture, emphasizing its role in custom silicon solutions [92][95]